Atypical Cogan's syndrome: a case report and summary of current treatment options
Jazyk angličtina Země Irsko Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
25600284
DOI
10.1016/j.ijporl.2014.12.028
PII: S0165-5876(14)00696-X
Knihovny.cz E-zdroje
- Klíčová slova
- Cogan's syndrome, Corticosteroids, Immunosuppressive therapy, Interstitial keratitis, Sensorineural hearing loss, Vertigo,
- MeSH
- azathioprin terapeutické užití MeSH
- Coganův syndrom diagnóza farmakoterapie MeSH
- glukokortikoidy terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- lidé MeSH
- methylprednisolon terapeutické užití MeSH
- mladiství MeSH
- nauzea etiologie MeSH
- oboustranná nedoslýchavost etiologie MeSH
- percepční nedoslýchavost etiologie MeSH
- vertigo etiologie MeSH
- zvracení etiologie MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- azathioprin MeSH
- glukokortikoidy MeSH
- imunosupresiva MeSH
- methylprednisolon MeSH
Cogan's syndrome is a rare chronic vasculitis, characterized in its typical form by progressive sensorineural bilateral hearing loss, vestibular symptoms and non-syphilitic interstitial keratitis. Only a few cases have been reported in children, most of whom have been diagnosed with the typical form. Early diagnosis and treatment are crucial to ensure a favorable prognosis. Systemic treatment usually begins with high dosage corticosteroids. In case the initial treatment fails, other immunosuppressive drugs are used (cyclophosphamide, methotrexate, cyclosporine A and azathioprine). Additional treatment possibilities, such as plasmapheresis, TNF-alpha blockers (etanercept and infliximab), rituximab, tocilizumab and mycophenolate mofetil have been described over the past few years.
Citace poskytuje Crossref.org
